Bridging a Pharma-Like Innovation Gap in Medical Nutrition

Weenen, Tamar; Fernald, Kenneth; Pronker, Esther; Commandeur, Harry; Claassen, Eric

doi:10.1007/978-3-319-06151-1_3

Cited by 7 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such transition in growth could mean the opposite, as it indicates a shift in the market from the growth phase into the maturity phase as we described earlier by Manfield's S-curve theory. 18 This transition is confirmed by comparing the non-cumulative patent filing graph with theory on patenting activity, thereby suggesting that optimal market penetration has already been reached. 15 Characteristic for a mature market is the negative technological progress over cumulative R&D expenditures.…”

Section: Discussionmentioning

confidence: 74%

Addressing the unmet need in respiratory viruses: an interdisciplinary analysis of product development pipeline in Asia

Feddema

Claassen

2018

Int J Clin Trials

Self Cite

View full text Add to dashboard Cite

Background: Respiratory tract infections (RTIs) pose a significant burden on health systems worldwide. Progress has been booked in reducing RTI disease burden through development of diagnostics, therapeutics and vaccines, though most efforts often fail to address the contribution of non-influenza viruses. Increasing awareness and the prevailing unmet need has resulted in the establishment of initiatives that aim to explore ways in which to extend innovation efforts for influenza to the broad range of respiratory viruses. This study will provide a detailed description of the state of the RTI market in Asia.Methods: By developing a dataset containing data from patent documents and clinical trials (CTs) we aimed to provide a detailed description of the RTI market in Asia.Results: We found a downward patent filing trend in respiratory diagnostics but a high number of phase 3 studies. A strong preference for the development of therapeutics and vaccines targeting bacterial pneumonia and influenza became apparent, whereas less attention is given towards product development targeting non-influenza viruses.Conclusions: The findings indicate a mature respiratory diagnostics market with minor industrial interest but at the same time an evolving RTI CT market with a strong late-stage pipeline. Asia represents only a handful of studies related to non-influenza viruses, mostly conducted by non-profit organisations. The business segment appears to focus upon product development for more profitable respiratory infections thereby suggesting that involvement and engagement of the industry within global initiatives and efforts to increase innovation for non-influenza viruses is not optimal.

show abstract

Section: Discussionmentioning

confidence: 74%

Addressing the unmet need in respiratory viruses: an interdisciplinary analysis of product development pipeline in Asia

Feddema

Claassen

2018

Int J Clin Trials

Self Cite

View full text Add to dashboard Cite

show abstract

“…The main conclusion of this paper implies a rather pessimistic scenario for early biotechnologies as the saturation or the maturity phase might be followed by an "innovation cliff" [32]. Early biotechnologies have reached their technological limit and there is a lack of newer radically innovative technologies that are currently generating product innovations.…”

Section: Discussionmentioning

confidence: 92%

“…In reference of the theory regarding technological development and innovation S-curves, rDNA and mAb technologies may have functioned as base technologies [37] for subsequent innovative technologies such as genomics and gene therapy that may spur a new S-curve of their own. In literature, this concept is described as "jumping the S-curve" [32,51]. Up to date, these subsequent technologies appear to have little to no impact on pharmaceutical productivity, as there are no examples of approved drugs that directly resulted from these technologies.…”

Section: Discussionmentioning

confidence: 99%

“…As Kickbusch & Payne (2003) [57] rightfully state, the line between foods, dietary supplements, and pharmaceutical products is becoming more difficult to draw. Weenen et al (2013b) [32] explain the differences and overlap between these product categories as well as convergence opportunities towards pharmanutrition. Another undeniable trend is the awareness and demand amongst end-users for increased functionality of foods in the context of healthy lifestyles including "healthy-ageing".…”

Section: Discussionmentioning

confidence: 99%

“…Application of this combination in the context of the industry as examined in this paper is difficult because invention and market introduction are two activities separated by 10 -14 years of R&D and hundreds of millions of R&D-spent US dollars [28,29]. In addition, conducting these separate activities requires very different knowledge, expertise, resources and capabilities, typically illustrated by the need for nimble biotech companies and incumbent pharmaceutical firms to work in collaborations and alliances [30][31][32]. This is one of the reasons why biotechnological inventions that might lead to a product are often described as innovations and patents are often used as a measure for biotechnological innovation [33,34].…”

Section: Innovationmentioning

confidence: 99%

See 2 more Smart Citations

Limits of Biotechnological Innovation

Fernald¹,

Weenen²,

Sibley³

et al. 2013

Self Cite

View full text Add to dashboard Cite

During the past two decades the biopharmaceutical industry has been facing an innovation deficit, characterized by increasing research & development costs and stagnant productivity. From its inception, biotechnology has been expected to counter this deficit by its revolutionary science-based approach to drug discovery. For this study we gathered patent and product data related to the technological development of the first two biotechnologies: recombinant DNA technology and monoclonal antibody technology. We studied the technological lifecycles of these technologies in terms of scientific discoveries and inventions as well as product innovations. Results indicate that over the years inventions related to these technologies have simultaneously become less radical and less valuable. Furthermore, our analysis shows that these biotechnologies have reached a stage of technological limit or saturation, which may be followed by an innovation cliff. Now, more than ever, it is crucial to examine new strategies and opportunities for value creation, capturing, and delivery, within the biopharmaceutical industry

show abstract

A critical appreciation of intangible resources in PharmaNutrition

et al. 2020

Self Cite

View full text Add to dashboard Cite

General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

show abstract

Bridging a Pharma-Like Innovation Gap in Medical Nutrition

Cited by 7 publications

References 50 publications

Addressing the unmet need in respiratory viruses: an interdisciplinary analysis of product development pipeline in Asia

Addressing the unmet need in respiratory viruses: an interdisciplinary analysis of product development pipeline in Asia

Limits of Biotechnological Innovation

A critical appreciation of intangible resources in PharmaNutrition

Contact Info

Product

Resources

About